What Is a Reference Listed Drug (RLD) and Why It Matters in Generic Development

A Reference Listed Drug (RLD) is the regulatory benchmark used in generic drug development to demonstrate pharmaceutical equivalence and bioequivalence.

A Reference Listed Drug (RLD) is the regulatory benchmark used in generic drug development to demonstrate pharmaceutical equivalence and bioequivalence. In an abbreviated pathway such as an ANDA (Abbreviated New Drug Application), the RLD defines the reference product against which a proposed generic product is compared.

For Regulatory Affairs, formulation, and bioequivalence (BE) teams, understanding the role of the Reference Listed Drug is foundational. The RLD is not simply a comparator product — it is the designated regulatory reference that anchors development, study design, and submission structure.

What Is a Reference Listed Drug (RLD)?

A Reference Listed Drug (RLD) is a previously approved drug product that a regulatory authority designates as the reference standard for generic development. In the United States, RLD designations are identified in the FDA Orange Book. Similar reference frameworks exist in other regulated markets.

The RLD establishes:

• The reference product identity
• Approved strength and dosage form
• Route of administration
• Labeling reference framework
• The product to which bioequivalence must be demonstrated

To demonstrate pharmaceutical equivalence, a generic product must match the Reference Listed Drug in active ingredient, strength, dosage form, and route of administration, subject to regulatory allowances.

Role of the RLD in Bioequivalence (BE) Studies

In a bioequivalence (BE) study, the Reference Listed Drug serves as the physical comparator product. The test (generic) product is administered alongside the RLD, and pharmacokinetic parameters — such as AUC and Cmax — are statistically compared.

The RLD therefore defines the benchmark exposure profile. Demonstrating bioequivalence means demonstrating statistical equivalence to the Reference Listed Drug.

Operational considerations that directly affect BE study integrity include:

• Correct identification of the designated RLD
• Representative commercial batch selection
• Batch and expiry traceability
• Storage and handling aligned with labeled conditions

Improper RLD identification or inadequate traceability may introduce regulatory questions during ANDA review.

Role of the RLD in an ANDA Submission

In an ANDA submission, the Reference Listed Drug functions as the regulatory anchor. The applicant must demonstrate that the proposed product is pharmaceutically equivalent and bioequivalent to the RLD.

Within the ANDA, the RLD is referenced to:

• Define the basis of comparison
• Support pharmaceutical equivalence claims
• Contextualize bioequivalence study results
• Align product characteristics and labeling references

Equivalence to the Reference Listed Drug is necessary in an abbreviated pathway, but regulatory decisions are based on the totality of evidence submitted.

RLD vs Comparator Product: Why Precision Matters

The term “comparator product” describes the functional role of a product used in a study. In many U.S.-focused ANDA programs, the comparator product and the Reference Listed Drug are the same.

However, in multi-jurisdictional development, the comparator selected for a BE study may not always align with the RLD designation in another regulatory region. For this reason, precise use of the term Reference Listed Drug (RLD) is important in regulatory documentation and development planning.

Operational Implications of RLD Selection

Because dissolution behavior, stability, and in-vivo performance can be influenced by batch characteristics and handling, RLD sourcing and traceability are practical development considerations.

Development teams commonly prioritize:

• Confirmed RLD designation
• Representative commercial batch availability
• Expiry window suitability
• Documented storage and handling integrity

These factors support defensible bioequivalence data generation.

Key Takeaways

• A Reference Listed Drug (RLD) is the designated regulatory reference for generic development.
• The RLD defines the benchmark for pharmaceutical equivalence and bioequivalence.
• In a BE study, the RLD is the physical comparator product.
• In an ANDA, the RLD is the regulatory reference framework.
• Accurate identification, traceability, and handling of the Reference Listed Drug support study integrity and regulatory clarity.

A structured generic development program begins with correct identification and understanding of the Reference Listed Drug (RLD).